SB26: Bill Text

SB26,4,4 4. The guidelines are created in an explicit and transparent process that does all of the following:

SB26,4,5 a. Minimizes biases and conflicts of interest.

SB26,4,6 b. Explains the relationship between treatment options and outcomes.

SB26,4,7 c. Rates the quality of evidence supporting recommendations.

SB26,4,8 d. Considers relevant patient subgroups and preferences.

SB26,4,10 5. The guidelines are continually updated through a review of new evidence and research and newly developed treatments.

SB26,4,12 (b) To satisfy par. (a) 2., the multidisciplinary panel of experts shall manage conflicts of interest among its members by doing all of the following:

SB26,4,16 1. Requiring members to disclose any potential conflict of interest to specific entities, including insurers, pharmacy benefit managers, and pharmaceutical manufacturers, and to recuse themselves from voting if they have a conflict of interest.

SB26,4,18 2. Using a methodology to provide objectivity in data analysis and ranking of evidence through the preparation of evidence tables and facilitating consensus.

SB26,4,19 3. Offering opportunities for public review and comments.

SB26,4,22 (c) An insurer, pharmacy benefit manager, or utilization review organization shall consider the needs of atypical patient populations and diagnoses when establishing clinical review criteria for the establishment of a step therapy protocol.

SB26,4,25 (d) Nothing in this subsection shall be construed to require insurers, pharmacy benefit managers, or the state to create a new entity to develop clinical review criteria used for step therapy protocols.

SB26,5,10 (3) Transparency of exceptions process. (a) When coverage of a prescription drug for the treatment of any medical condition is restricted for use by an insurer, pharmacy benefit manager, or utilization review organization through the use of a step therapy protocol, the insurer, pharmacy benefit manager, or utilization review organization shall provide access to a clear, readily accessible and convenient process to request an exception to the step therapy protocol. An insurer, pharmacy benefit manager, or utilization review organization may use any existing medical exceptions process to satisfy the requirement under this paragraph. The exception process shall be made easily accessible on the Internet site of the insurer, pharmacy benefit manager, or utilization review organization.

SB26,5,13 (b) An insurer, pharmacy benefit manager, or utilization review organization shall expeditiously grant an exception to the step therapy protocol if any of the following are satisfied:

SB26,5,16 1. The prescription drug required under the step therapy protocol is contraindicated or will likely cause an adverse reaction by or physical or mental harm to the patient.

SB26,5,19 2. The prescription drug required under the step therapy protocol is expected to be ineffective based on the known clinical characteristics of the patient and the known characteristics of the prescription drug regimen.

SB26,5,24 3. The patient has tried the prescription drug required under the step therapy protocol, or another prescription drug in the same pharmacologic class or with the same mechanism of action, under the policy or plan or a previous policy or plan and the patient's use of the prescription drug was discontinued due to lack of efficacy or effectiveness, diminished effect, or an adverse event.

SB26,6,3 4. Based on an evaluation of medically necessary drugs for the patient's condition, the prescription drug required under the step therapy protocol is not in the best interest of the patient.

SB26,6,6 5. The patient is stable on a prescription drug selected by his or her health care provider for the medical condition under consideration while covered under the policy or plan or a previous policy or plan.

SB26,6,10 (c) Upon granting an exception to the step therapy protocol under par. (b), the insurer, pharmacy benefit manager, or utilization review organization shall authorize coverage for the prescription drug prescribed by the patient's treating health care provider.

SB26,6,12 (d) An insured may appeal any request for an exception to the step therapy protocol that is denied.

SB26,6,21 (e) An insurer, pharmacy benefit manager, or utilization review organization shall grant or deny a request for any exception to the step therapy protocol within 72 hours of receipt of the request or the request to appeal the previous decision. In exigent circumstances, an insurer, pharmacy benefit manager, or utilization review organization shall grant or deny a request for an exception to the step therapy protocol within 24 hours of receipt of the request. If the insurer, pharmacy benefit manager, or utilization review organization does not grant or deny a request or an appeal under the time specified under this paragraph, the exception is considered granted.

SB26,6,22 (f) Nothing in this subsection shall be construed to prevent any of the following:

SB26,7,2 1. An insurer, pharmacy benefit manager, or utilization review organization from requiring a patient to try an AB-rated generic equivalent prescription drug, as designated by the federal food and drug administration, before providing coverage for the equivalent brand name prescription drug.

SB26,7,4 2. A health care provider from prescribing a prescription drug that is determined to be medically appropriate.

SB26,7,6 (4) Rules. The commissioner shall promulgate any rules necessary to implement or enforce this section.

SB26,2 Section 2 . Initial applicability.

SB26,7,10 (1) For policies and plans containing provisions inconsistent with this act, the act first applies to policy or plan years beginning on January 1 of the year following the year in which this subsection takes effect.

SB26,3 Section 3 . Effective date.

SB26,7,13 (1) This act takes effect on the first day of the 4th month beginning after publication.

SB26,7,14 (End)